Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Ligand provided Evomela data. Was going through their 2015 Roth presentation and they had a slide that provided this interesting info:

•Positive pivotal trial data presented in detail at 2015 BMT Tandem Meeting in February

- Overall response rate improved from 79% at study entry to 95% following CE-Melphalan and transplant

- Complete response rate increased from 10%  to 31%

•NDA submitted in December and action and  launch expected by year-end

•Product profile could lead to rapid adoption[Bold mine]


Also I see some discussion on the Yahoo board about Ligand indicating that revenue from Evomela could be in the 30M range which would translate into 150M in Evomela sales. That # is not new. At Ligand Analyst Day (Nov 18, 2014) they had 'Peak Potential Revenue Range to Ligand' >30M.